| Revenue growth | +110.9% YoY consolidated; +45.4% QoQ |
|---|---|
| Margins | Standalone GM 34.8% vs 44.1%; Innoxel EBITDA 32.9% |
| Order book | ₹117.83 Cr: tenders ₹65.6 Cr, exports ₹30.73 Cr, intl ₹21.5 Cr |
| Demand visibility | Order book ₹117.83 Cr at 30-Sep-26 |
Growth
Standalone revenue ₹78.6 Cr (+88.4% YoY); Innoxel ₹44.5 Cr (+253.1%); Varenyam ₹19.7 Cr (+33.2%). H1 +27.3%.
Outlook
Innoxel FY27 OL revenue guide ₹70-90 Cr, EBITDA margin 20-25%; Varenyam Bio Phase 1 capex ₹300 Cr.
Risks
Standalone gross margin fell to 34.8% from 44.1% YoY; Varenyam revenue down 21.5% QoQ; Innoxel revenue lumpy, supply ramp H2-dependent.
Investor Presentation filed with BSE, NSE: BPLPHARMA. Summary written with AI assistance from the document.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹1,938.05
- Market cap
- ₹1,336 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- -86.7×Sector 46.1×
- Promoter holding
- 67.20%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Q2 FY27 Results: Turns Profitable, Net Profit ₹11.8 Cr
Bharat Parenterals approved unaudited standalone results for the quarter ended 30 September 2026. The company reported profit and revenue growth versus the prior-year quarter.
- Key figure
- Net profit ₹11.8 Cr
Bharat Parenterals Board Meeting Date
Bharat Parenterals will hold a board meeting on October 29, 2026 to consider unaudited standalone and consolidated results. Trading window has been closed since October 1, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals held an EGM via video conferencing on October 23, 2026. Members considered a preferential equity issue and Section 186 investment and guarantee limits.
Bharat Parenterals Business Update
Innoxel Lifesciences, a Bharat Parenterals subsidiary, began U.S. commercial supply of its first CMO product. This adds recurring manufacturing revenue to its existing licensing income.
Bharat Parenterals Preferential Issue
Bharat Parenterals filed a corrigendum to its EGM notice for a preferential issue exceeding ₹100 Crore. It adds a Crisil monitoring agency disclosure per BSE direction.
Bharat Parenterals Other Announcement
Bharat Parenterals Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, as per regulatory requirements.